Sign in
CompletedPhase 2

A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa

Key facts

Who runs it
Tulane University
Where
Covington and New Orleans, United StatesSee the 4 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
10 people enrolled
Started
25 Sept 2025
Ended
28 Sept 2026
Type of study
Interventional
Treatments tested
  • Topical roflumilast 0.3% foam
Record updated
9 October 2026

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Must understand the risks and the benefits/purpose of the study and provide signed and dated informed consent
  • Must be 18 years at time of signing informed consent form
  • Willing to participate in all required evaluations and procedures in the study including the ability to apply topical medication without difficulty
  • Patients must have a diagnosis of HS based upon the clinical criteria of a history of more than or equal 5 typical lesions (erythematous papules, nodules, or abscesses) in flexural sites with a recurring nature over time
  • Patients must be candidate for topical therapy defined by active Hurley stage I or Hurley stage II/III with active disease after an adequate trial of systemic antibiotics/hormonal/immunomodulatory or biologic therapy
  • Patient is required to be on stable dose of concomitant therapy for at least 3 months before enrollment and throughout the study period
  • Females of childbearing potential must have a negative urine pregnancy test at baseline visit and be on adequate contraception throughout the study time

Who cannot take part

  • Concomitant use of topical antibiotics, topical corticosteroids, resorcinol, benzoyl peroxide, vitamin D analogs, Hibiclens wash (except for emollients) within 1 week of enrollment
  • Increasing or changing dosing for concurrent therapy agents within 90 days before study day 0 and during the study period
  • Prior major surgery or major life-threatening medical illness within 2 weeks
  • Any severe systemic illness requiring Intravenous (IV) antibiotics within the two weeks prior to initiation of the study drug
  • Active substance abuse or a history of substance abuse within 6 months prior to screening
  • Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer)
  • History of any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major uncontrolled disease
  • Active hepatitis B or C infection with detectible viral nucleic acid in the blood or known Human Immunodeficiency Virus (HIV) positivity
  • Patients with known active malignancy
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Pregnant or breastfeeding

Where in United States

  • Lakeview HospitalCovington, United States
  • Lakeside HospitalNew Orleans, United States
  • LCMC Multi-speciality ClinicNew Orleans, United States
  • University Medical CenterNew Orleans, United States

About the trial

What the trial wants to find out

This is a phase 2a, open label study.

Read full original descriptionShow less

As psoriasis and Hidradenitis Suppurativa (HS) share multiple inflammatory pathways, the investigators hypothesize that the use of topical roflumilast 0.3% foam is a safe and efficacious option as a monotherapy for patients with mild disease and as add-on therapy for maintenance and flares in patients with moderate to severe disease. The study will include correlative analysis to study gene expression profiling before and after therapy.

The group in the trial

  • HS patients armTreatment being tested

    Patients must have a diagnosis of HS based upon the clinical criteria of a history of more or equal than 5 typical lesions (erythematous papules, nodules, or abscesses) in flexural sites with a recurring nature over time. Patients must be candidate for topical therapy defined by active Hurley stage I or Hurley stage II/III with active disease after an adequate trial of systemic antibiotics/hormonal/immunomodulatory or biologic therapy.

    Treatment: Topical roflumilast 0.3% foam

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open Label Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam as a Mono or add-on Therapy in the Treatment of Hidradenitis Suppurativa With Correlative Analysis.
Record updated
9 October 2026